#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Bacterial Membrane Vesicles , which respond to the extracellular vesicles ( EVs )
2-1	16-25	Bacterial	object[3]	new[3]	_	_
2-2	26-34	Membrane	object|object[3]	new|new[3]	coref	3-5
2-3	35-43	Vesicles	object[3]	new[3]	_	_
2-4	44-45	,	object[3]	new[3]	_	_
2-5	46-51	which	object[3]	new[3]	_	_
2-6	52-59	respond	object[3]	new[3]	_	_
2-7	60-62	to	object[3]	new[3]	_	_
2-8	63-66	the	object[3]|abstract[4]	new[3]|new[4]	appos	2-12[0_4]
2-9	67-80	extracellular	object[3]|abstract[4]	new[3]|new[4]	_	_
2-10	81-89	vesicles	object[3]|abstract[4]	new[3]|new[4]	_	_
2-11	90-91	(	_	_	_	_
2-12	92-95	EVs	abstract	giv	coref	5-6
2-13	96-97	)	_	_	_	_

#Text=definition criteria , are membrane structures , produced by Gram-negative , Gram-positive and Mycobacteria microorganisms during their growth .
3-1	98-108	definition	abstract|abstract[7]	new|new[7]	coref	3-5[9_7]
3-2	109-117	criteria	abstract[7]	new[7]	_	_
3-3	118-119	,	_	_	_	_
3-4	120-123	are	_	_	_	_
3-5	124-132	membrane	object|abstract[9]	giv|giv[9]	ana|coref	3-17[0_9]|7-9[48_0]
3-6	133-143	structures	abstract[9]	giv[9]	_	_
3-7	144-145	,	abstract[9]	giv[9]	_	_
3-8	146-154	produced	abstract[9]	giv[9]	_	_
3-9	155-157	by	abstract[9]	giv[9]	_	_
3-10	158-171	Gram-negative	abstract[9]|animal[10]	giv[9]|new[10]	_	_
3-11	172-173	,	abstract[9]|animal[10]	giv[9]|new[10]	_	_
3-12	174-187	Gram-positive	abstract[9]|animal[10]	giv[9]|new[10]	_	_
3-13	188-191	and	abstract[9]|animal[10]	giv[9]|new[10]	_	_
3-14	192-204	Mycobacteria	abstract[9]|animal[10]	giv[9]|new[10]	_	_
3-15	205-219	microorganisms	abstract[9]|animal[10]	giv[9]|new[10]	_	_
3-16	220-226	during	abstract[9]	giv[9]	_	_
3-17	227-232	their	abstract[9]|abstract|abstract[12]	giv[9]|giv|new[12]	coref	10-33[0_12]
3-18	233-239	growth	abstract[9]|abstract[12]	giv[9]|new[12]	_	_
3-19	240-241	.	_	_	_	_

#Text=These elements are spherical in shape , with an average size in the range from 20 to 500 nm and deliver several components , such as proteins , nucleic acids , and phospholipids .
4-1	242-247	These	abstract[13]	new[13]	_	_
4-2	248-256	elements	abstract[13]	new[13]	_	_
4-3	257-260	are	_	_	_	_
4-4	261-270	spherical	_	_	_	_
4-5	271-273	in	_	_	_	_
4-6	274-279	shape	abstract	new	_	_
4-7	280-281	,	_	_	_	_
4-8	282-286	with	_	_	_	_
4-9	287-289	an	abstract[15]	new[15]	_	_
4-10	290-297	average	abstract[15]	new[15]	_	_
4-11	298-302	size	abstract[15]	new[15]	_	_
4-12	303-305	in	abstract[15]	new[15]	_	_
4-13	306-309	the	abstract[15]|abstract[16]	new[15]|new[16]	_	_
4-14	310-315	range	abstract[15]|abstract[16]	new[15]|new[16]	_	_
4-15	316-320	from	abstract[15]|abstract[16]	new[15]|new[16]	_	_
4-16	321-323	20	abstract[15]|abstract[16]|abstract[17]	new[15]|new[16]|new[17]	ana	5-1[0_17]
4-17	324-326	to	abstract[15]|abstract[16]|abstract[17]	new[15]|new[16]|new[17]	_	_
4-18	327-330	500	abstract[15]|abstract[16]|abstract[17]	new[15]|new[16]|new[17]	_	_
4-19	331-333	nm	abstract[15]|abstract[16]|abstract[17]	new[15]|new[16]|new[17]	_	_
4-20	334-337	and	_	_	_	_
4-21	338-345	deliver	_	_	_	_
4-22	346-353	several	abstract[18]	new[18]	_	_
4-23	354-364	components	abstract[18]	new[18]	_	_
4-24	365-366	,	abstract[18]	new[18]	_	_
4-25	367-371	such	abstract[18]	new[18]	_	_
4-26	372-374	as	abstract[18]	new[18]	_	_
4-27	375-383	proteins	abstract[18]|substance	new[18]|new	_	_
4-28	384-385	,	abstract[18]	new[18]	_	_
4-29	386-393	nucleic	abstract[18]|substance[20]	new[18]|new[20]	_	_
4-30	394-399	acids	abstract[18]|substance[20]	new[18]|new[20]	_	_
4-31	400-401	,	abstract[18]	new[18]	_	_
4-32	402-405	and	abstract[18]	new[18]	_	_
4-33	406-419	phospholipids	abstract[18]|abstract	new[18]|new	_	_
4-34	420-421	.	_	_	_	_

#Text=It has been reported that EVs are involved in a number of physiological and pathological mechanisms , including biofilm formation , inter-cellular cross-talk , as well as bacteria – host and bacterium – phage interactions .
5-1	422-424	It	abstract	giv	_	_
5-2	425-428	has	_	_	_	_
5-3	429-433	been	_	_	_	_
5-4	434-442	reported	_	_	_	_
5-5	443-447	that	_	_	_	_
5-6	448-451	EVs	abstract	giv	coref	6-10
5-7	452-455	are	_	_	_	_
5-8	456-464	involved	_	_	_	_
5-9	465-467	in	_	_	_	_
5-10	468-469	a	abstract[24]	new[24]	_	_
5-11	470-476	number	abstract[24]	new[24]	_	_
5-12	477-479	of	abstract[24]	new[24]	_	_
5-13	480-493	physiological	abstract[24]	new[24]	_	_
5-14	494-497	and	abstract[24]	new[24]	_	_
5-15	498-510	pathological	abstract[24]	new[24]	_	_
5-16	511-521	mechanisms	abstract[24]	new[24]	_	_
5-17	522-523	,	abstract[24]	new[24]	_	_
5-18	524-533	including	abstract[24]	new[24]	_	_
5-19	534-541	biofilm	abstract[24]|substance|event[26]	new[24]|new|new[26]	coref	13-26
5-20	542-551	formation	abstract[24]|event[26]	new[24]|new[26]	_	_
5-21	552-553	,	abstract[24]	new[24]	_	_
5-22	554-568	inter-cellular	abstract[24]|abstract[27]	new[24]|new[27]	_	_
5-23	569-579	cross-talk	abstract[24]|abstract[27]	new[24]|new[27]	_	_
5-24	580-581	,	abstract[24]	new[24]	_	_
5-25	582-584	as	abstract[24]	new[24]	_	_
5-26	585-589	well	abstract[24]	new[24]	_	_
5-27	590-592	as	abstract[24]	new[24]	_	_
5-28	593-601	bacteria	abstract[24]|animal|animal[29]|abstract[33]	new[24]|new|new[29]|new[33]	coref	7-24[51_29]
5-29	602-603	–	abstract[24]|animal[29]|abstract[33]	new[24]|new[29]|new[33]	_	_
5-30	604-608	host	abstract[24]|animal[29]|animal|abstract[33]	new[24]|new[29]|new|new[33]	_	_
5-31	609-612	and	abstract[24]|animal[29]|abstract[33]	new[24]|new[29]|new[33]	_	_
5-32	613-622	bacterium	abstract[24]|animal[29]|animal|abstract[33]	new[24]|new[29]|new|new[33]	coref	18-53[183_0]
5-33	623-624	–	abstract[24]|animal[29]|abstract[33]	new[24]|new[29]|new[33]	_	_
5-34	625-630	phage	abstract[24]|animal[29]|abstract|abstract[33]	new[24]|new[29]|new|new[33]	_	_
5-35	631-643	interactions	abstract[24]|abstract[33]	new[24]|new[33]	_	_
5-36	644-645	.	_	_	_	_

#Text=Many studies support the hypothesis that the generation of EVs is a controlled and regulated process , although Turnbull et al. demonstrated that the EVs ’ biogenesis is associated with a rearrangement of the bacterial membranes , derived from lysed cells , which incorporate soluble molecules .
6-1	646-650	Many	abstract[34]	new[34]	_	_
6-2	651-658	studies	abstract[34]	new[34]	_	_
6-3	659-666	support	_	_	_	_
6-4	667-670	the	abstract[35]	new[35]	_	_
6-5	671-681	hypothesis	abstract[35]	new[35]	_	_
6-6	682-686	that	abstract[35]	new[35]	_	_
6-7	687-690	the	abstract[35]|event[36]|event[38]	new[35]|new[36]|new[38]	_	_
6-8	691-701	generation	abstract[35]|event[36]|event[38]	new[35]|new[36]|new[38]	_	_
6-9	702-704	of	abstract[35]|event[36]|event[38]	new[35]|new[36]|new[38]	_	_
6-10	705-708	EVs	abstract[35]|event[36]|abstract|event[38]	new[35]|new[36]|giv|new[38]	coref	7-6
6-11	709-711	is	abstract[35]|event[38]	new[35]|new[38]	_	_
6-12	712-713	a	abstract[35]|event[38]	new[35]|new[38]	_	_
6-13	714-724	controlled	abstract[35]|event[38]	new[35]|new[38]	_	_
6-14	725-728	and	abstract[35]|event[38]	new[35]|new[38]	_	_
6-15	729-738	regulated	abstract[35]|event[38]	new[35]|new[38]	_	_
6-16	739-746	process	abstract[35]|event[38]	new[35]|new[38]	_	_
6-17	747-748	,	_	_	_	_
6-18	749-757	although	_	_	_	_
6-19	758-766	Turnbull	person	new	_	_
6-20	767-769	et	_	_	_	_
6-21	770-773	al.	_	_	_	_
6-22	774-786	demonstrated	_	_	_	_
6-23	787-791	that	_	_	_	_
6-24	792-795	the	abstract[41]	new[41]	ana	7-1[0_41]
6-25	796-799	EVs	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-26	800-801	’	abstract[40]|abstract[41]	new[40]|new[41]	_	_
6-27	802-812	biogenesis	abstract[41]	new[41]	_	_
6-28	813-815	is	_	_	_	_
6-29	816-826	associated	_	_	_	_
6-30	827-831	with	_	_	_	_
6-31	832-833	a	event[42]	new[42]	_	_
6-32	834-847	rearrangement	event[42]	new[42]	_	_
6-33	848-850	of	event[42]	new[42]	_	_
6-34	851-854	the	event[42]|object[43]	new[42]|new[43]	_	_
6-35	855-864	bacterial	event[42]|object[43]	new[42]|new[43]	_	_
6-36	865-874	membranes	event[42]|object[43]	new[42]|new[43]	_	_
6-37	875-876	,	event[42]|object[43]	new[42]|new[43]	_	_
6-38	877-884	derived	event[42]|object[43]	new[42]|new[43]	_	_
6-39	885-889	from	event[42]|object[43]	new[42]|new[43]	_	_
6-40	890-895	lysed	event[42]|object[43]|object[44]	new[42]|new[43]|new[44]	coref	7-13[49_44]
6-41	896-901	cells	event[42]|object[43]|object[44]	new[42]|new[43]|new[44]	_	_
6-42	902-903	,	event[42]|object[43]	new[42]|new[43]	_	_
6-43	904-909	which	event[42]|object[43]	new[42]|new[43]	_	_
6-44	910-921	incorporate	event[42]|object[43]	new[42]|new[43]	_	_
6-45	922-929	soluble	event[42]|object[43]|substance[45]	new[42]|new[43]|new[45]	_	_
6-46	930-939	molecules	event[42]|object[43]|substance[45]	new[42]|new[43]|new[45]	_	_
6-47	940-941	.	_	_	_	_

#Text=It is also known that EVs fuse with the outer membrane of Gram-negative cells , while they are not able to interact with Gram-positive bacteria .
7-1	942-944	It	abstract	giv	ana	8-1
7-2	945-947	is	_	_	_	_
7-3	948-952	also	_	_	_	_
7-4	953-958	known	_	_	_	_
7-5	959-963	that	_	_	_	_
7-6	964-967	EVs	abstract	giv	ana	7-17
7-7	968-972	fuse	_	_	_	_
7-8	973-977	with	_	_	_	_
7-9	978-981	the	object[48]	giv[48]	_	_
7-10	982-987	outer	object[48]	giv[48]	_	_
7-11	988-996	membrane	object[48]	giv[48]	_	_
7-12	997-999	of	object[48]	giv[48]	_	_
7-13	1000-1013	Gram-negative	object[48]|object[49]	giv[48]|giv[49]	ana	8-18[0_49]
7-14	1014-1019	cells	object[48]|object[49]	giv[48]|giv[49]	_	_
7-15	1020-1021	,	_	_	_	_
7-16	1022-1027	while	_	_	_	_
7-17	1028-1032	they	abstract	giv	coref	8-5[53_0]
7-18	1033-1036	are	_	_	_	_
7-19	1037-1040	not	_	_	_	_
7-20	1041-1045	able	_	_	_	_
7-21	1046-1048	to	_	_	_	_
7-22	1049-1057	interact	_	_	_	_
7-23	1058-1062	with	_	_	_	_
7-24	1063-1076	Gram-positive	animal[51]	giv[51]	_	_
7-25	1077-1085	bacteria	animal[51]	giv[51]	_	_
7-26	1086-1087	.	_	_	_	_

#Text=It was demonstrated that EVs stemming from Pseudomonas aeruginosa are able to interact with Shigella flexneri pouring their content into the periplasm of eukaryotic cells ;
8-1	1088-1090	It	abstract	giv	_	_
8-2	1091-1094	was	_	_	_	_
8-3	1095-1107	demonstrated	_	_	_	_
8-4	1108-1112	that	_	_	_	_
8-5	1113-1116	EVs	abstract[53]	giv[53]	coref	9-3[61_53]
8-6	1117-1125	stemming	abstract[53]	giv[53]	_	_
8-7	1126-1130	from	abstract[53]	giv[53]	_	_
8-8	1131-1142	Pseudomonas	abstract[53]|animal|animal[55]	giv[53]|new|new[55]	coref	14-11[0_55]
8-9	1143-1153	aeruginosa	abstract[53]|animal[55]	giv[53]|new[55]	_	_
8-10	1154-1157	are	_	_	_	_
8-11	1158-1162	able	_	_	_	_
8-12	1163-1165	to	_	_	_	_
8-13	1166-1174	interact	_	_	_	_
8-14	1175-1179	with	_	_	_	_
8-15	1180-1188	Shigella	person[56]	new[56]	_	_
8-16	1189-1197	flexneri	person[56]	new[56]	_	_
8-17	1198-1205	pouring	_	_	_	_
8-18	1206-1211	their	object|abstract[58]	giv|new[58]	coref|coref	8-24[60_0]|10-5[0_58]
8-19	1212-1219	content	abstract[58]	new[58]	_	_
8-20	1220-1224	into	_	_	_	_
8-21	1225-1228	the	substance[59]	new[59]	_	_
8-22	1229-1238	periplasm	substance[59]	new[59]	_	_
8-23	1239-1241	of	substance[59]	new[59]	_	_
8-24	1242-1252	eukaryotic	substance[59]|object[60]	new[59]|giv[60]	coref	11-54[99_60]
8-25	1253-1258	cells	substance[59]|object[60]	new[59]|giv[60]	_	_
8-26	1259-1260	;	_	_	_	_

#Text=conversely , EVs derived from P. aeruginosa adhere to the cell wall of Staphylococcus aureus .
9-1	1261-1271	conversely	_	_	_	_
9-2	1272-1273	,	_	_	_	_
9-3	1274-1277	EVs	abstract[61]	giv[61]	coref	10-2[0_61]
9-4	1278-1285	derived	abstract[61]	giv[61]	_	_
9-5	1286-1290	from	abstract[61]	giv[61]	_	_
9-6	1291-1293	P.	abstract[61]|animal[62]	giv[61]|new[62]	coref	14-10[0_62]
9-7	1294-1304	aeruginosa	abstract[61]|animal[62]	giv[61]|new[62]	_	_
9-8	1305-1311	adhere	_	_	_	_
9-9	1312-1314	to	_	_	_	_
9-10	1315-1318	the	object[64]	new[64]	_	_
9-11	1319-1323	cell	place|object[64]	new|new[64]	_	_
9-12	1324-1328	wall	object[64]	new[64]	_	_
9-13	1329-1331	of	object[64]	new[64]	_	_
9-14	1332-1346	Staphylococcus	object[64]|animal[65]	new[64]|new[65]	_	_
9-15	1347-1353	aureus	object[64]|animal[65]	new[64]|new[65]	_	_
9-16	1354-1355	.	_	_	_	_

#Text=The EVs composition and content are strictly dependent on the environmental conditions where they are generated , as well as on the bacterial species from which they are produced and on their growth phase .
10-1	1356-1359	The	abstract[67]	new[67]	coref	13-31[121_67]
10-2	1360-1363	EVs	abstract|abstract[67]	giv|new[67]	coref	11-8
10-3	1364-1375	composition	abstract[67]	new[67]	_	_
10-4	1376-1379	and	_	_	_	_
10-5	1380-1387	content	abstract	giv	coref	13-8
10-6	1388-1391	are	_	_	_	_
10-7	1392-1400	strictly	_	_	_	_
10-8	1401-1410	dependent	_	_	_	_
10-9	1411-1413	on	_	_	_	_
10-10	1414-1417	the	abstract[69]	new[69]	ana	10-14[0_69]
10-11	1418-1431	environmental	abstract[69]	new[69]	_	_
10-12	1432-1442	conditions	abstract[69]	new[69]	_	_
10-13	1443-1448	where	abstract[69]	new[69]	_	_
10-14	1449-1453	they	abstract[69]|abstract	new[69]|giv	ana	10-27
10-15	1454-1457	are	abstract[69]	new[69]	_	_
10-16	1458-1467	generated	abstract[69]	new[69]	_	_
10-17	1468-1469	,	_	_	_	_
10-18	1470-1472	as	_	_	_	_
10-19	1473-1477	well	_	_	_	_
10-20	1478-1480	as	_	_	_	_
10-21	1481-1483	on	_	_	_	_
10-22	1484-1487	the	plant[71]|plant[72]	new[71]|new[72]	ana	11-60[0_72]
10-23	1488-1497	bacterial	plant[71]|plant[72]	new[71]|new[72]	_	_
10-24	1498-1505	species	plant[71]|plant[72]	new[71]|new[72]	_	_
10-25	1506-1510	from	plant[71]|plant[72]	new[71]|new[72]	_	_
10-26	1511-1516	which	plant[71]|plant[72]	new[71]|new[72]	_	_
10-27	1517-1521	they	plant[71]|plant[72]|abstract	new[71]|new[72]|giv	ana	10-32
10-28	1522-1525	are	plant[71]|plant[72]	new[71]|new[72]	_	_
10-29	1526-1534	produced	plant[71]|plant[72]	new[71]|new[72]	_	_
10-30	1535-1538	and	plant[72]	new[72]	_	_
10-31	1539-1541	on	plant[72]	new[72]	_	_
10-32	1542-1547	their	plant[72]|abstract|abstract[76]	new[72]|giv|new[76]	coref|coref	11-4[77_0]|13-14[115_76]
10-33	1548-1554	growth	plant[72]|abstract|abstract[76]	new[72]|giv|new[76]	coref	13-15
10-34	1555-1560	phase	plant[72]|abstract[76]	new[72]|new[76]	_	_
10-35	1561-1562	.	_	_	_	_

#Text=For example , iron-limiting conditions increase the EVs production from Helicobacter pylori , Haemophilus influenzae , Escherichia coli , and Vibrio cholera ; the oxygen availability affects the generation of EVs and the antibiotic treatment ( i.e. , polymyxin B or colistin ) promotes an increase of EVs production that confers protection to the bacterial cells , thus allowing their survival .
11-1	1563-1566	For	_	_	_	_
11-2	1567-1574	example	_	_	_	_
11-3	1575-1576	,	_	_	_	_
11-4	1577-1590	iron-limiting	abstract[77]	giv[77]	coref	19-19[191_77]
11-5	1591-1601	conditions	abstract[77]	giv[77]	_	_
11-6	1602-1610	increase	_	_	_	_
11-7	1611-1614	the	abstract[79]	new[79]	coref	11-48[97_79]
11-8	1615-1618	EVs	abstract|abstract[79]	giv|new[79]	coref	11-31
11-9	1619-1629	production	abstract[79]	new[79]	_	_
11-10	1630-1634	from	abstract[79]	new[79]	_	_
11-11	1635-1647	Helicobacter	abstract[79]|plant|person[81]	new[79]|new|new[81]	coref	15-1[134_81]
11-12	1648-1654	pylori	abstract[79]|person[81]	new[79]|new[81]	_	_
11-13	1655-1656	,	abstract[79]	new[79]	_	_
11-14	1657-1668	Haemophilus	abstract[79]|abstract[82]	new[79]|new[82]	_	_
11-15	1669-1679	influenzae	abstract[79]|abstract[82]	new[79]|new[82]	_	_
11-16	1680-1681	,	abstract[79]	new[79]	_	_
11-17	1682-1693	Escherichia	abstract[79]|abstract[83]|abstract[84]	new[79]|new[83]|giv[84]	coref	11-17[84_83]
11-18	1694-1698	coli	abstract[79]|abstract[83]|abstract[84]	new[79]|new[83]|giv[84]	_	_
11-19	1699-1700	,	abstract[79]|abstract[83]|abstract[84]	new[79]|new[83]|giv[84]	_	_
11-20	1701-1704	and	abstract[79]|abstract[83]|abstract[84]	new[79]|new[83]|giv[84]	_	_
11-21	1705-1711	Vibrio	abstract[79]|abstract[83]|abstract[84]|person	new[79]|new[83]|giv[84]|new	_	_
11-22	1712-1719	cholera	abstract[79]|abstract[83]|abstract[84]	new[79]|new[83]|giv[84]	_	_
11-23	1720-1721	;	_	_	_	_
11-24	1722-1725	the	abstract[87]	new[87]	_	_
11-25	1726-1732	oxygen	substance|abstract[87]	new|new[87]	_	_
11-26	1733-1745	availability	abstract[87]	new[87]	_	_
11-27	1746-1753	affects	_	_	_	_
11-28	1754-1757	the	person[88]	new[88]	_	_
11-29	1758-1768	generation	person[88]	new[88]	_	_
11-30	1769-1771	of	person[88]	new[88]	_	_
11-31	1772-1775	EVs	person[88]|abstract	new[88]|giv	coref	11-48
11-32	1776-1779	and	_	_	_	_
11-33	1780-1783	the	abstract[90]	new[90]	appos	11-37[93_90]
11-34	1784-1794	antibiotic	abstract[90]	new[90]	_	_
11-35	1795-1804	treatment	abstract[90]	new[90]	_	_
11-36	1805-1806	(	_	_	_	_
11-37	1807-1811	i.e.	place[92]|abstract[93]	new[92]|giv[93]	_	_
11-38	1812-1813	,	place[92]|abstract[93]	new[92]|giv[93]	_	_
11-39	1814-1823	polymyxin	person|place[92]|abstract[93]	new|new[92]|giv[93]	_	_
11-40	1824-1825	B	place[92]|abstract[93]	new[92]|giv[93]	_	_
11-41	1826-1828	or	abstract[93]	giv[93]	_	_
11-42	1829-1837	colistin	abstract[93]|substance	giv[93]|new	_	_
11-43	1838-1839	)	_	_	_	_
11-44	1840-1848	promotes	_	_	_	_
11-45	1849-1851	an	event[95]	new[95]	_	_
11-46	1852-1860	increase	event[95]	new[95]	_	_
11-47	1861-1863	of	event[95]	new[95]	_	_
11-48	1864-1867	EVs	event[95]|abstract|abstract[97]	new[95]|giv|giv[97]	coref|coref	12-16[107_97]|12-19[108_0]
11-49	1868-1878	production	event[95]|abstract[97]	new[95]|giv[97]	_	_
11-50	1879-1883	that	event[95]|abstract[97]	new[95]|giv[97]	_	_
11-51	1884-1891	confers	event[95]|abstract[97]	new[95]|giv[97]	_	_
11-52	1892-1902	protection	event[95]|abstract[97]|abstract	new[95]|giv[97]|new	_	_
11-53	1903-1905	to	event[95]|abstract[97]	new[95]|giv[97]	_	_
11-54	1906-1909	the	event[95]|abstract[97]|object[99]	new[95]|giv[97]|giv[99]	coref	16-13[148_99]
11-55	1910-1919	bacterial	event[95]|abstract[97]|object[99]	new[95]|giv[97]|giv[99]	_	_
11-56	1920-1925	cells	event[95]|abstract[97]|object[99]	new[95]|giv[97]|giv[99]	_	_
11-57	1926-1927	,	_	_	_	_
11-58	1928-1932	thus	_	_	_	_
11-59	1933-1941	allowing	_	_	_	_
11-60	1942-1947	their	plant|event[101]	giv|new[101]	_	_
11-61	1948-1956	survival	event[101]	new[101]	_	_
11-62	1957-1958	.	_	_	_	_

#Text=A previous study , performed on Stenotrophomonas maltophilia , demonstrated that the imipenem treatment increases the production of EVs delivering β-lactamases .
12-1	1959-1960	A	abstract[102]	new[102]	_	_
12-2	1961-1969	previous	abstract[102]	new[102]	_	_
12-3	1970-1975	study	abstract[102]	new[102]	_	_
12-4	1976-1977	,	abstract[102]	new[102]	_	_
12-5	1978-1987	performed	abstract[102]	new[102]	_	_
12-6	1988-1990	on	abstract[102]	new[102]	_	_
12-7	1991-2007	Stenotrophomonas	abstract[102]|abstract|animal[104]	new[102]|new|new[104]	_	_
12-8	2008-2019	maltophilia	abstract[102]|animal[104]	new[102]|new[104]	_	_
12-9	2020-2021	,	_	_	_	_
12-10	2022-2034	demonstrated	_	_	_	_
12-11	2035-2039	that	_	_	_	_
12-12	2040-2043	the	event[106]	new[106]	_	_
12-13	2044-2052	imipenem	substance|event[106]	new|new[106]	_	_
12-14	2053-2062	treatment	event[106]	new[106]	_	_
12-15	2063-2072	increases	_	_	_	_
12-16	2073-2076	the	abstract[107]	giv[107]	_	_
12-17	2077-2087	production	abstract[107]	giv[107]	_	_
12-18	2088-2090	of	abstract[107]	giv[107]	_	_
12-19	2091-2094	EVs	abstract[107]|abstract[108]	giv[107]|giv[108]	coref	13-5[0_108]
12-20	2095-2105	delivering	abstract[107]|abstract[108]	giv[107]|giv[108]	_	_
12-21	2106-2118	β-lactamases	abstract[107]|abstract[108]|substance	giv[107]|giv[108]|new	_	_
12-22	2119-2120	.	_	_	_	_

#Text=Modifications in terms of EVs production and content might also be associated with the growth phase , as well as with the bacterial phenotype ( biofilm or planktonic ) and the media composition .
13-1	2121-2134	Modifications	abstract[110]	new[110]	coref	19-13[187_110]
13-2	2135-2137	in	abstract[110]	new[110]	_	_
13-3	2138-2143	terms	abstract[110]	new[110]	_	_
13-4	2144-2146	of	abstract[110]	new[110]	_	_
13-5	2147-2150	EVs	abstract[110]|abstract|abstract[112]	new[110]|giv|new[112]	coref|coref	14-6[123_0]|19-16[190_112]
13-6	2151-2161	production	abstract[110]|abstract[112]	new[110]|new[112]	_	_
13-7	2162-2165	and	abstract[110]	new[110]	_	_
13-8	2166-2173	content	abstract[110]|abstract	new[110]|giv	_	_
13-9	2174-2179	might	_	_	_	_
13-10	2180-2184	also	_	_	_	_
13-11	2185-2187	be	_	_	_	_
13-12	2188-2198	associated	_	_	_	_
13-13	2199-2203	with	_	_	_	_
13-14	2204-2207	the	abstract[115]	giv[115]	_	_
13-15	2208-2214	growth	abstract|abstract[115]	giv|giv[115]	_	_
13-16	2215-2220	phase	abstract[115]	giv[115]	_	_
13-17	2221-2222	,	_	_	_	_
13-18	2223-2225	as	_	_	_	_
13-19	2226-2230	well	_	_	_	_
13-20	2231-2233	as	_	_	_	_
13-21	2234-2238	with	_	_	_	_
13-22	2239-2242	the	abstract[116]	new[116]	appos	13-26[118_116]
13-23	2243-2252	bacterial	abstract[116]	new[116]	_	_
13-24	2253-2262	phenotype	abstract[116]	new[116]	_	_
13-25	2263-2264	(	_	_	_	_
13-26	2265-2272	biofilm	substance|abstract[118]	giv|giv[118]	appos|coref	13-28[0_118]|14-12
13-27	2273-2275	or	abstract[118]	giv[118]	_	_
13-28	2276-2286	planktonic	abstract[118]|abstract	giv[118]|giv	_	_
13-29	2287-2288	)	_	_	_	_
13-30	2289-2292	and	_	_	_	_
13-31	2293-2296	the	abstract[121]	giv[121]	_	_
13-32	2297-2302	media	substance|abstract[121]	new|giv[121]	_	_
13-33	2303-2314	composition	abstract[121]	giv[121]	_	_
13-34	2315-2316	.	_	_	_	_

#Text=Park et al. demonstrated that EVs associated to the P. aeruginosa biofilm phenotype showed a unique proteome profile , with respect to the one carried by EVs stemming from its planktonic counterpart .
14-1	2317-2321	Park	person	new	_	_
14-2	2322-2324	et	_	_	_	_
14-3	2325-2328	al.	_	_	_	_
14-4	2329-2341	demonstrated	_	_	_	_
14-5	2342-2346	that	_	_	_	_
14-6	2347-2350	EVs	abstract[123]	giv[123]	coref	14-27[131_123]
14-7	2351-2361	associated	abstract[123]	giv[123]	_	_
14-8	2362-2364	to	abstract[123]	giv[123]	_	_
14-9	2365-2368	the	abstract[123]|abstract[127]	giv[123]|new[127]	coref	17-9[160_127]
14-10	2369-2371	P.	abstract[123]|animal|abstract[127]	giv[123]|giv|new[127]	_	_
14-11	2372-2382	aeruginosa	abstract[123]|animal|abstract[127]	giv[123]|giv|new[127]	_	_
14-12	2383-2390	biofilm	abstract[123]|substance|abstract[127]	giv[123]|giv|new[127]	coref	16-48[156_0]
14-13	2391-2400	phenotype	abstract[123]|abstract[127]	giv[123]|new[127]	_	_
14-14	2401-2407	showed	_	_	_	_
14-15	2408-2409	a	abstract[129]	new[129]	_	_
14-16	2410-2416	unique	abstract[129]	new[129]	_	_
14-17	2417-2425	proteome	abstract|abstract[129]	new|new[129]	_	_
14-18	2426-2433	profile	abstract[129]	new[129]	_	_
14-19	2434-2435	,	abstract[129]	new[129]	_	_
14-20	2436-2440	with	abstract[129]	new[129]	_	_
14-21	2441-2448	respect	abstract[129]	new[129]	_	_
14-22	2449-2451	to	abstract[129]	new[129]	_	_
14-23	2452-2455	the	abstract[129]|abstract[130]	new[129]|new[130]	_	_
14-24	2456-2459	one	abstract[129]|abstract[130]	new[129]|new[130]	_	_
14-25	2460-2467	carried	abstract[129]|abstract[130]	new[129]|new[130]	_	_
14-26	2468-2470	by	abstract[129]|abstract[130]	new[129]|new[130]	_	_
14-27	2471-2474	EVs	abstract[129]|abstract[130]|abstract[131]	new[129]|new[130]|giv[131]	ana	14-30[0_131]
14-28	2475-2483	stemming	abstract[129]|abstract[130]|abstract[131]	new[129]|new[130]|giv[131]	_	_
14-29	2484-2488	from	abstract[129]|abstract[130]|abstract[131]	new[129]|new[130]|giv[131]	_	_
14-30	2489-2492	its	abstract[129]|abstract[130]|abstract[131]|abstract|abstract[133]	new[129]|new[130]|giv[131]|giv|new[133]	coref	15-23
14-31	2493-2503	planktonic	abstract[129]|abstract[130]|abstract[131]|abstract[133]	new[129]|new[130]|giv[131]|new[133]	_	_
14-32	2504-2515	counterpart	abstract[129]|abstract[130]|abstract[131]|abstract[133]	new[129]|new[130]|giv[131]|new[133]	_	_
14-33	2516-2517	.	_	_	_	_

#Text=Helicobacter pylori ATCC 43629 and Lactobacillus reuteri DSM 17938 are biofilm-producing strains , and both the planktonic and the biofilm phenotypes generate EVs ( pEVs and bEVs , respectively ) carrying extracellular DNA ( eDNA). .
15-1	2518-2530	Helicobacter	person[134]|abstract[135]	giv[134]|new[135]	coref|coref	18-57[0_134]|18-58[0_135]
15-2	2531-2537	pylori	person[134]|abstract[135]	giv[134]|new[135]	_	_
15-3	2538-2542	ATCC	abstract[135]	new[135]	_	_
15-4	2543-2548	43629	_	_	_	_
15-5	2549-2552	and	_	_	_	_
15-6	2553-2566	Lactobacillus	abstract[136]|animal[137]	new[136]|new[137]	coref	15-11[138_137]
15-7	2567-2574	reuteri	abstract[136]|animal[137]	new[136]|new[137]	_	_
15-8	2575-2578	DSM	animal[137]	new[137]	_	_
15-9	2579-2584	17938	animal[137]	new[137]	_	_
15-10	2585-2588	are	_	_	_	_
15-11	2589-2606	biofilm-producing	animal[138]	giv[138]	_	_
15-12	2607-2614	strains	animal[138]	giv[138]	_	_
15-13	2615-2616	,	_	_	_	_
15-14	2617-2620	and	_	_	_	_
15-15	2621-2625	both	abstract[139]	new[139]	coref	18-46[177_139]
15-16	2626-2629	the	abstract[139]	new[139]	_	_
15-17	2630-2640	planktonic	abstract[139]	new[139]	_	_
15-18	2641-2644	and	abstract[139]	new[139]	_	_
15-19	2645-2648	the	abstract[139]	new[139]	_	_
15-20	2649-2656	biofilm	abstract[139]	new[139]	_	_
15-21	2657-2667	phenotypes	abstract[139]	new[139]	_	_
15-22	2668-2676	generate	_	_	_	_
15-23	2677-2680	EVs	abstract	giv	appos	15-25
15-24	2681-2682	(	_	_	_	_
15-25	2683-2687	pEVs	abstract|abstract[142]	giv|giv[142]	appos|appos	15-25[142_0]|15-27[143_142]
15-26	2688-2691	and	abstract[142]	giv[142]	_	_
15-27	2692-2696	bEVs	abstract[142]|abstract[143]	giv[142]|giv[143]	coref	16-4[147_143]
15-28	2697-2698	,	abstract[142]|abstract[143]	giv[142]|giv[143]	_	_
15-29	2699-2711	respectively	abstract[142]|abstract[143]	giv[142]|giv[143]	_	_
15-30	2712-2713	)	_	_	_	_
15-31	2714-2722	carrying	_	_	_	_
15-32	2723-2736	extracellular	abstract[144]	new[144]	appos	15-35[0_144]
15-33	2737-2740	DNA	abstract[144]	new[144]	_	_
15-34	2741-2742	(	_	_	_	_
15-35	2743-2749	eDNA).	abstract	giv	_	_
15-36	2750-2751	.	_	_	_	_

#Text=In particular , H. pylori -derived bEVs seemed to “ bridge ” bacterial cells , thus playing a possible structural role ; however , the fact that eDNA are carried by EVs , may protect the eDNA from the enzymatic activity of DNase I in breaking up the biofilm .
16-1	2752-2754	In	_	_	_	_
16-2	2755-2765	particular	_	_	_	_
16-3	2766-2767	,	_	_	_	_
16-4	2768-2770	H.	person[146]|abstract[147]	new[146]|giv[147]	coref|coref	16-32[0_147]|18-56[0_146]
16-5	2771-2777	pylori	person[146]|abstract[147]	new[146]|giv[147]	_	_
16-6	2778-2786	-derived	abstract[147]	giv[147]	_	_
16-7	2787-2791	bEVs	abstract[147]	giv[147]	_	_
16-8	2792-2798	seemed	_	_	_	_
16-9	2799-2801	to	_	_	_	_
16-10	2802-2803	“	_	_	_	_
16-11	2804-2810	bridge	_	_	_	_
16-12	2811-2812	”	_	_	_	_
16-13	2813-2822	bacterial	object[148]	giv[148]	_	_
16-14	2823-2828	cells	object[148]	giv[148]	_	_
16-15	2829-2830	,	_	_	_	_
16-16	2831-2835	thus	_	_	_	_
16-17	2836-2843	playing	_	_	_	_
16-18	2844-2845	a	abstract[149]	new[149]	_	_
16-19	2846-2854	possible	abstract[149]	new[149]	_	_
16-20	2855-2865	structural	abstract[149]	new[149]	_	_
16-21	2866-2870	role	abstract[149]	new[149]	_	_
16-22	2871-2872	;	_	_	_	_
16-23	2873-2880	however	_	_	_	_
16-24	2881-2882	,	_	_	_	_
16-25	2883-2886	the	abstract[150]	new[150]	_	_
16-26	2887-2891	fact	abstract[150]	new[150]	_	_
16-27	2892-2896	that	abstract[150]	new[150]	_	_
16-28	2897-2901	eDNA	abstract[150]|abstract	new[150]|new	coref	16-36[153_0]
16-29	2902-2905	are	abstract[150]	new[150]	_	_
16-30	2906-2913	carried	abstract[150]	new[150]	_	_
16-31	2914-2916	by	abstract[150]	new[150]	_	_
16-32	2917-2920	EVs	abstract[150]|abstract	new[150]|giv	coref	17-6[158_0]
16-33	2921-2922	,	_	_	_	_
16-34	2923-2926	may	_	_	_	_
16-35	2927-2934	protect	_	_	_	_
16-36	2935-2938	the	abstract[153]	giv[153]	coref	17-17[0_153]
16-37	2939-2943	eDNA	abstract[153]	giv[153]	_	_
16-38	2944-2948	from	_	_	_	_
16-39	2949-2952	the	abstract[154]	new[154]	ana	17-1[0_154]
16-40	2953-2962	enzymatic	abstract[154]	new[154]	_	_
16-41	2963-2971	activity	abstract[154]	new[154]	_	_
16-42	2972-2974	of	abstract[154]	new[154]	_	_
16-43	2975-2980	DNase	abstract[154]|substance[155]	new[154]|new[155]	_	_
16-44	2981-2982	I	abstract[154]|substance[155]	new[154]|new[155]	_	_
16-45	2983-2985	in	_	_	_	_
16-46	2986-2994	breaking	_	_	_	_
16-47	2995-2997	up	_	_	_	_
16-48	2998-3001	the	substance[156]	giv[156]	coref	17-10[0_156]
16-49	3002-3009	biofilm	substance[156]	giv[156]	_	_
16-50	3010-3011	.	_	_	_	_

#Text=It cannot be dismissed that EVs produced from the biofilm phenotype may represent a shuttle for eDNA transport .
17-1	3012-3014	It	abstract	giv	_	_
17-2	3015-3021	cannot	_	_	_	_
17-3	3022-3024	be	_	_	_	_
17-4	3025-3034	dismissed	_	_	_	_
17-5	3035-3039	that	_	_	_	_
17-6	3040-3043	EVs	abstract[158]	giv[158]	coref	18-29[173_158]
17-7	3044-3052	produced	abstract[158]	giv[158]	_	_
17-8	3053-3057	from	abstract[158]	giv[158]	_	_
17-9	3058-3061	the	abstract[158]|abstract[160]	giv[158]|giv[160]	_	_
17-10	3062-3069	biofilm	abstract[158]|substance|abstract[160]	giv[158]|giv|giv[160]	_	_
17-11	3070-3079	phenotype	abstract[158]|abstract[160]	giv[158]|giv[160]	_	_
17-12	3080-3083	may	_	_	_	_
17-13	3084-3093	represent	_	_	_	_
17-14	3094-3095	a	object[161]	new[161]	_	_
17-15	3096-3103	shuttle	object[161]	new[161]	_	_
17-16	3104-3107	for	object[161]	new[161]	_	_
17-17	3108-3112	eDNA	object[161]|abstract|event[163]	new[161]|giv|new[163]	_	_
17-18	3113-3122	transport	object[161]|event[163]	new[161]|new[163]	_	_
17-19	3123-3124	.	_	_	_	_

#Text=For all of these reasons , we aimed to optimize a simplified Polychromatic Flow Cytometry ( PFC ) method for a fast identification , enumeration and characterization of bacterial derived EVs , as well as for the analysis of their eDNA-associated subtypes , produced by the planktonic and the biofilm phenotypes of a Gram-negative ( H. pylori ATCC 43629 ) and a Gram-positive ( L. reuteri DSM 17938 ) bacterium .
18-1	3125-3128	For	_	_	_	_
18-2	3129-3132	all	abstract[164]	new[164]	_	_
18-3	3133-3135	of	abstract[164]	new[164]	_	_
18-4	3136-3141	these	abstract[164]	new[164]	_	_
18-5	3142-3149	reasons	abstract[164]	new[164]	_	_
18-6	3150-3151	,	_	_	_	_
18-7	3152-3154	we	person	acc	ana	19-1
18-8	3155-3160	aimed	_	_	_	_
18-9	3161-3163	to	_	_	_	_
18-10	3164-3172	optimize	_	_	_	_
18-11	3173-3174	a	abstract[169]	new[169]	_	_
18-12	3175-3185	simplified	abstract[169]	new[169]	_	_
18-13	3186-3199	Polychromatic	abstract[169]	new[169]	_	_
18-14	3200-3204	Flow	abstract|abstract[167]|abstract[169]	new|new[167]|new[169]	appos	18-17[0_167]
18-15	3205-3214	Cytometry	abstract[167]|abstract[169]	new[167]|new[169]	_	_
18-16	3215-3216	(	abstract[169]	new[169]	_	_
18-17	3217-3220	PFC	abstract|abstract[169]	giv|new[169]	coref	19-4
18-18	3221-3222	)	abstract[169]	new[169]	_	_
18-19	3223-3229	method	abstract[169]	new[169]	_	_
18-20	3230-3233	for	abstract[169]	new[169]	_	_
18-21	3234-3235	a	abstract[169]|abstract[170]	new[169]|new[170]	_	_
18-22	3236-3240	fast	abstract[169]|abstract[170]	new[169]|new[170]	_	_
18-23	3241-3255	identification	abstract[169]|abstract[170]	new[169]|new[170]	_	_
18-24	3256-3257	,	abstract[169]	new[169]	_	_
18-25	3258-3269	enumeration	abstract[169]|abstract	new[169]|new	coref	19-30[193_0]
18-26	3270-3273	and	abstract[169]	new[169]	_	_
18-27	3274-3290	characterization	abstract[169]|abstract[172]	new[169]|new[172]	_	_
18-28	3291-3293	of	abstract[169]|abstract[172]	new[169]|new[172]	_	_
18-29	3294-3303	bacterial	abstract[169]|abstract[172]|abstract[173]	new[169]|new[172]|giv[173]	ana	18-40[0_173]
18-30	3304-3311	derived	abstract[169]|abstract[172]|abstract[173]	new[169]|new[172]|giv[173]	_	_
18-31	3312-3315	EVs	abstract[169]|abstract[172]|abstract[173]	new[169]|new[172]|giv[173]	_	_
18-32	3316-3317	,	_	_	_	_
18-33	3318-3320	as	_	_	_	_
18-34	3321-3325	well	_	_	_	_
18-35	3326-3328	as	_	_	_	_
18-36	3329-3332	for	_	_	_	_
18-37	3333-3336	the	abstract[174]	new[174]	_	_
18-38	3337-3345	analysis	abstract[174]	new[174]	_	_
18-39	3346-3348	of	abstract[174]	new[174]	_	_
18-40	3349-3354	their	abstract[174]|abstract|abstract[176]	new[174]|giv|new[176]	coref	19-16
18-41	3355-3370	eDNA-associated	abstract[174]|abstract[176]	new[174]|new[176]	_	_
18-42	3371-3379	subtypes	abstract[174]|abstract[176]	new[174]|new[176]	_	_
18-43	3380-3381	,	abstract[174]|abstract[176]	new[174]|new[176]	_	_
18-44	3382-3390	produced	abstract[174]|abstract[176]	new[174]|new[176]	_	_
18-45	3391-3393	by	abstract[174]|abstract[176]	new[174]|new[176]	_	_
18-46	3394-3397	the	abstract[174]|abstract[176]|abstract[177]	new[174]|new[176]|giv[177]	_	_
18-47	3398-3408	planktonic	abstract[174]|abstract[176]|abstract[177]	new[174]|new[176]|giv[177]	_	_
18-48	3409-3412	and	abstract[174]|abstract[176]|abstract[177]	new[174]|new[176]|giv[177]	_	_
18-49	3413-3416	the	abstract[174]|abstract[176]|abstract[177]	new[174]|new[176]|giv[177]	_	_
18-50	3417-3424	biofilm	abstract[174]|abstract[176]|abstract[177]	new[174]|new[176]|giv[177]	_	_
18-51	3425-3435	phenotypes	abstract[174]|abstract[176]|abstract[177]	new[174]|new[176]|giv[177]	_	_
18-52	3436-3438	of	abstract[174]|abstract[176]|abstract[177]	new[174]|new[176]|giv[177]	_	_
18-53	3439-3440	a	abstract[174]|abstract[176]|abstract[177]|animal[183]	new[174]|new[176]|giv[177]|giv[183]	_	_
18-54	3441-3454	Gram-negative	abstract[174]|abstract[176]|abstract[177]|animal[183]	new[174]|new[176]|giv[177]|giv[183]	_	_
18-55	3455-3456	(	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-56	3457-3459	H.	abstract[174]|abstract[176]|abstract[177]|person|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|giv|new[181]|giv[183]	_	_
18-57	3460-3466	pylori	abstract[174]|abstract[176]|abstract[177]|person|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|giv|new[181]|giv[183]	_	_
18-58	3467-3471	ATCC	abstract[174]|abstract[176]|abstract[177]|abstract|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|giv|new[181]|giv[183]	_	_
18-59	3472-3477	43629	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-60	3478-3479	)	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-61	3480-3483	and	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-62	3484-3485	a	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-63	3486-3499	Gram-positive	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-64	3500-3501	(	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-65	3502-3504	L.	abstract[174]|abstract[176]|abstract[177]|abstract[181]|person|animal[183]	new[174]|new[176]|giv[177]|new[181]|new|giv[183]	_	_
18-66	3505-3512	reuteri	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-67	3513-3516	DSM	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-68	3517-3522	17938	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-69	3523-3524	)	abstract[174]|abstract[176]|abstract[177]|abstract[181]|animal[183]	new[174]|new[176]|giv[177]|new[181]|giv[183]	_	_
18-70	3525-3534	bacterium	abstract[174]|abstract[176]|abstract[177]|animal[183]	new[174]|new[176]|giv[177]|giv[183]	_	_
18-71	3535-3536	.	_	_	_	_

#Text=We demonstrated that PFC can be used as a tool to study the modifications of EVs production under different environmental conditions , as well as for the detection and enumeration of bacterial derived EVs , and in particular eDNA-associated EVs , in clinical samples .
19-1	3537-3539	We	person	giv	_	_
19-2	3540-3552	demonstrated	_	_	_	_
19-3	3553-3557	that	_	_	_	_
19-4	3558-3561	PFC	abstract	giv	_	_
19-5	3562-3565	can	_	_	_	_
19-6	3566-3568	be	_	_	_	_
19-7	3569-3573	used	_	_	_	_
19-8	3574-3576	as	_	_	_	_
19-9	3577-3578	a	abstract[186]	new[186]	_	_
19-10	3579-3583	tool	abstract[186]	new[186]	_	_
19-11	3584-3586	to	abstract[186]	new[186]	_	_
19-12	3587-3592	study	abstract[186]	new[186]	_	_
19-13	3593-3596	the	abstract[186]|abstract[187]|abstract[188]	new[186]|giv[187]|giv[188]	coref	19-13[188_187]
19-14	3597-3610	modifications	abstract[186]|abstract[187]|abstract[188]	new[186]|giv[187]|giv[188]	_	_
19-15	3611-3613	of	abstract[186]|abstract[187]|abstract[188]	new[186]|giv[187]|giv[188]	_	_
19-16	3614-3617	EVs	abstract[186]|abstract[187]|abstract[188]|abstract|abstract[190]	new[186]|giv[187]|giv[188]|giv|giv[190]	coref	19-32[194_0]
19-17	3618-3628	production	abstract[186]|abstract[187]|abstract[188]|abstract[190]	new[186]|giv[187]|giv[188]|giv[190]	_	_
19-18	3629-3634	under	abstract[186]|abstract[187]|abstract[188]|abstract[190]	new[186]|giv[187]|giv[188]|giv[190]	_	_
19-19	3635-3644	different	abstract[186]|abstract[187]|abstract[188]|abstract[190]|abstract[191]	new[186]|giv[187]|giv[188]|giv[190]|giv[191]	_	_
19-20	3645-3658	environmental	abstract[186]|abstract[187]|abstract[188]|abstract[190]|abstract[191]	new[186]|giv[187]|giv[188]|giv[190]|giv[191]	_	_
19-21	3659-3669	conditions	abstract[186]|abstract[187]|abstract[188]|abstract[190]|abstract[191]	new[186]|giv[187]|giv[188]|giv[190]|giv[191]	_	_
19-22	3670-3671	,	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-23	3672-3674	as	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-24	3675-3679	well	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-25	3680-3682	as	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-26	3683-3686	for	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-27	3687-3690	the	abstract[186]|abstract[188]|abstract[192]	new[186]|giv[188]|new[192]	_	_
19-28	3691-3700	detection	abstract[186]|abstract[188]|abstract[192]	new[186]|giv[188]|new[192]	_	_
19-29	3701-3704	and	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-30	3705-3716	enumeration	abstract[186]|abstract[188]|abstract[193]	new[186]|giv[188]|giv[193]	_	_
19-31	3717-3719	of	abstract[186]|abstract[188]|abstract[193]	new[186]|giv[188]|giv[193]	_	_
19-32	3720-3729	bacterial	abstract[186]|abstract[188]|abstract[193]|abstract[194]	new[186]|giv[188]|giv[193]|giv[194]	coref	19-38[196_194]
19-33	3730-3737	derived	abstract[186]|abstract[188]|abstract[193]|abstract[194]	new[186]|giv[188]|giv[193]|giv[194]	_	_
19-34	3738-3741	EVs	abstract[186]|abstract[188]|abstract[193]|abstract[194]	new[186]|giv[188]|giv[193]|giv[194]	_	_
19-35	3742-3743	,	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-36	3744-3747	and	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-37	3748-3750	in	abstract[186]|abstract[188]	new[186]|giv[188]	_	_
19-38	3751-3761	particular	abstract[186]|abstract[188]|abstract[196]	new[186]|giv[188]|giv[196]	_	_
19-39	3762-3777	eDNA-associated	abstract[186]|abstract[188]|abstract|abstract[196]	new[186]|giv[188]|new|giv[196]	_	_
19-40	3778-3781	EVs	abstract[186]|abstract[188]|abstract[196]	new[186]|giv[188]|giv[196]	_	_
19-41	3782-3783	,	abstract[186]|abstract[188]|abstract[196]	new[186]|giv[188]|giv[196]	_	_
19-42	3784-3786	in	abstract[186]|abstract[188]|abstract[196]	new[186]|giv[188]|giv[196]	_	_
19-43	3787-3795	clinical	abstract[186]|abstract[188]|abstract[196]|object[197]	new[186]|giv[188]|giv[196]|new[197]	_	_
19-44	3796-3803	samples	abstract[186]|abstract[188]|abstract[196]|object[197]	new[186]|giv[188]|giv[196]|new[197]	_	_
19-45	3804-3805	.	_	_	_	_
